CA Patent

CA2619919C — Diaminopyrimidines as p2x3 and p2x2/3 modulators

Assigned to F Hoffmann La Roche AG · Expires 2014-04-01 · 12y expired

What this patent protects

Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I), wherein D, X, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined h…

USPTO Abstract

Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I), wherein D, X, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.

Drugs covered by this patent

Patent Metadata

Patent number
CA2619919C
Jurisdiction
CA
Classification
—
Expires
2014-04-01
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.